Search research articles
Contact Us
Filters
Showing results (921-930 of 4,104) with videos related to
Page
of 411
Sort By:
Cancer Cell
|
February 21, 2025
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
Patrizia Porazzi, Siena Nason, Ziqi Yang, et al.
Cancer Cell
|
February 11, 2025
Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma
Julia Schiantarelli, Mouadh Benamar, Jihye Park, et al.
Cancer Cell
|
January 31, 2025
Circulating T cells fuel anti-PD-1 and lenvatinib efficacy
Peter J Matulich, Megan L Burger
Cancer Cell
|
November 15, 2024
Itaconate promotes an unexpected tumor immune escape mechanism
Lara Haase, Christian Frezza
Cancer Cell
|
November 1, 2024
Targeting DLK1 in neuroblastoma
John Anderson
Cancer Cell
|
November 1, 2024
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Diwakar Davar, Robert M Morrison, Amiran K Dzutsev, et al.
Cancer Cell
|
November 1, 2024
Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma
James W Smithy, Michael A Postow
Cancer Cell
|
November 8, 2024
Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance
Heng Lin, Kole Tison, Yuheng Du, et al.
Cancer Cell
|
March 21, 2025
Horizontal mitochondrial transfer in cancer biology: Potential clinical relevance
Michael V Berridge, Renata Zobalova, Stepana Boukalova, et al.
Cancer Cell
|
March 14, 2025
PAI-1-driven SFRP2<sup>high</sup> cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy
Yan-Pei Zhang, Ze-Qin Guo, Xiao-Ting Cai, et al.
Page
of 411
Search research articles
Search
Showing results (921-930 of 4,104) with videos related to
Sort By:
Page
of 411
Cancer Cell
|
February 21, 2025
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
Patrizia Porazzi, Siena Nason, Ziqi Yang, et al.
Cancer Cell
|
February 11, 2025
Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma
Julia Schiantarelli, Mouadh Benamar, Jihye Park, et al.
Cancer Cell
|
January 31, 2025
Circulating T cells fuel anti-PD-1 and lenvatinib efficacy
Peter J Matulich, Megan L Burger
Cancer Cell
|
November 15, 2024
Itaconate promotes an unexpected tumor immune escape mechanism
Lara Haase, Christian Frezza
Cancer Cell
|
November 1, 2024
Targeting DLK1 in neuroblastoma
John Anderson
Cancer Cell
|
November 1, 2024
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Diwakar Davar, Robert M Morrison, Amiran K Dzutsev, et al.
Cancer Cell
|
November 1, 2024
Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma
James W Smithy, Michael A Postow
Cancer Cell
|
November 8, 2024
Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance
Heng Lin, Kole Tison, Yuheng Du, et al.
Cancer Cell
|
March 21, 2025
Horizontal mitochondrial transfer in cancer biology: Potential clinical relevance
Michael V Berridge, Renata Zobalova, Stepana Boukalova, et al.
Cancer Cell
|
March 14, 2025
PAI-1-driven SFRP2<sup>high</sup> cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy
Yan-Pei Zhang, Ze-Qin Guo, Xiao-Ting Cai, et al.
Page
of 411